Ensaios Clínicos Atuais

Clinical Trials

Study Title	Minimum Age	Maximum age	Who Can Join?	Phase	Status
A phase I, single-center, open-label, two-period, cross-over, fixed-sequence study to assess the effect of Clarithromycin 500mg on the pharmacokinetics of BIA 28-6156 60mg and the effect of BIA 28-6156 60mg on the PK of Midazolam 2 mg and Dabigatran etexilate 150mg, in healthy subjects (BIA-28-6156-113) Parkinson Disease, Drug-Drug Interaction NCT06597084	18	65	All	1	At the screening visit
Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate (BIA-2093-213) Epilepsy, stroke NCT06597084	30	80	All	2	Finalised. Public disclosure ongoing
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene (BIA-28-6156-201) Parkinson Disease, GBA1 gene, Pathogenic variant NCT05819359	35	80	All	2	Recruitment terminated
A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson’s Disease Patients, with an Open-Label Extension (BIA-91067-303) Early Parkinson Disease NCT04978597	30	80	All	3	Finalised. Public disclosure ongoing
Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson's disease patients with end-of-dose motor fluctuations and associated pain (BIA-91067-404) Parkinson Disease, Motor fluctuations, Pain NCT04986982	30	n.a.	All	4	Finalised. Public disclosure ongoing